Last Updated:
Searching
Create account to add to watchlist!

Medicus Sciences Acquisition Corp. - MSAC

  • Commons

    $9.75

    +0.10%

    MSAC Vol: 1.3K

  • Warrants

    $0.82

    -0.18%

    MSACW Vol: 1.9K

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 90.4M
Average Volume: 26.1K
52W Range: $9.58 - $10.29
Weekly %: +0.31%
Monthly %: +0.41%
Inst Owners: 49

Info

Target: Searching
Days Since IPO: 284
Unit composition:
Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-ninth of one Outstanding Redeemable Warrant (or 888,889 Outstanding Redeemable Warrants in the aggregate)
Trust Size: 8000000.0M

Management

Our officers, directors and director nominees are as follows: Name ​ ​ Age ​ ​ Position ​ Jacob Gottlieb, M.D. ​ ​ ​ ​ 49 ​ ​ ​ Executive Chairman ​ Michael Castor, M.D. ​ ​ ​ ​ 49 ​ ​ ​ Chief Executive Officer & Director ​ Eric Cheng ​ ​ ​ ​ 51 ​ ​ ​ Chief Business Officer ​ Judah Drillick ​ ​ ​ ​ 44 ​ ​ ​ Chief Financial Officer ​ Kenneth Berkovitz, M.D., F.A.C.C. ​ ​ ​ ​ 46 ​ ​ ​ Director nominee ​ Christopher Kaster ​ ​ ​ ​ 49 ​ ​ ​ Director nominee ​ Ross Levine, M.D. ​ ​ ​ ​ 48 ​ ​ ​ Director nominee ​ Jacob Gottlieb, M.D. has served as our Executive Chairman since our inception in November 2020. Dr. Gottlieb is the Managing Partner and Chief Investment Officer of Altium Capital Management, LP, a healthcare-focused alternative asset manager and affiliate of our sponsor, a role he has held since he founded Altium in 2017. Prior to founding Altium, Dr. Gottlieb founded Visium Asset Management, a healthcare-focused investment firm, which was spun out from Balyasny Asset Management in 2005. Under Dr. Gottlieb’s leadership as Managing Member and Chief Investment Officer of Visium from 2005 to 2016, Visium grew to approximately $8 billion in assets under management, employing over 175 people in New York, San Francisco and London. Prior to founding Visium, from 2001 to 2005, Dr. Gottlieb was the Healthcare Portfolio Manager and Partner at Balyasny Asset Management, an investment management firm, where he built his team to over 20 investment professionals prior to spinning out to form Visium. Before joining Balyasny, he was a Portfolio Manager at Merlin BioMed, a healthcare-focused investment firm. Dr. Gottlieb started his investment career as a buy-side analyst at Sanford C. Bernstein (now AllianceBernstein), an investment firm, covering global healthcare. Dr. Gottlieb earned his B.A. from Brown University, where he graduated magna cum laude, then attended New York University Medical School where he earned his M.D. in 1997. Dr. Gottlieb obtained his Chartered Financial Analyst (CFA) charter in 2001, and his Professional Risk Manager (PRM) designation in 2010. We believe Dr. Gottlieb is well-qualified to serve as a member of our board of directors due to his experience in asset management, and his contacts and relationships. Michael Castor, M.D. has served as our Chief Executive Officer and Director since our inception in November 2020. Dr. Castor founded Sio Capital Management, LLC, a healthcare-focused investment firm and affiliate of our sponsor, in 2006 and has served as the portfolio manager since its inception. Before starting Sio, Dr. Castor worked at Bernstein Investment Research and Management from 2001 to 2006 as the firm’s healthcare analyst and as the healthcare sector leader. Prior to Bernstein, Dr. Castor worked in the investment banking/equity capital markets division of JP Morgan from 2000 to 2001, where he focused on biotechnology and healthcare equity offerings. Before entering finance, Dr. Castor spent three years in clinical medicine. He completed his surgery internship at Indiana University Medical Center in 1998 followed by two years of surgery and otolaryngology residency at Columbia Presbyterian Medical Center in New York. Dr. Castor earned his M.D. from The Ohio State University College of Medicine, where he graduated summa cum laude. He earned his undergraduate degree in Biomedical Engineering from Tulane University where he graduated summa cum laude with departmental honors. We believe Dr. Castor is well-qualified to serve as a member of our board of directors due to his experience in asset management, and his contacts and relationships. Eric Cheng has served as our Chief Business Officer since our inception in November 2020. Mr. Cheng joined Altium in 2020 as a Managing Director focused on investments in the private capital markets and special situations within the healthcare sector. Prior to Altium, Mr. Cheng spent approximately 23 years as an investment banker during which time he completed approximately 200 financing and mergers and acquisitions transactions, representing over $13 billion in aggregate value. From 2017 to 2020, Mr. Cheng was Managing Director and Co-Head of Healthcare Investment Banking at Roth Capital Partners, an investment bank, where he managed the firm’s life sciences investment banking business. Prior to Roth, from 2011 to 2017, Mr. Cheng was Senior Managing Director and Head of Healthcare Investment Banking at 122 TABLE OF CONTENTS Maxim, an investment bank. From 2005 to 2011, Mr. Cheng was a senior life sciences banker at BMO Capital Markets, the global investment banking subsidiary of the Bank of Montreal. Mr. Cheng also held investment banking roles at WR Hambrecht & Co. from 2002 to 2005, Deutsche Bank Securities from 2000 to 2002 and Lehman Brothers from 1997 to 2000. Mr. Cheng began his career as a public accountant at Deloitte & Touche in 1992 and earned his B.A. from the University of California at Los Angeles and his M.B.A. from Columbia Business School. Judah Drillick has been our Chief Financial Officer since our inception in November 2020. Mr. Drillick is the Chief Financial Officer and Chief Compliance Officer of Sio, where he has led the firm’s accounting, operations, and compliance functions at Sio since 2015. Mr. Drillick has over 16 year of accounting experience at several financial firms. Prior to Sio, Mr. Drillick served as Controller for Stillwater Capital Partners from 2013 to 2015 and Controller of Cross River Bank from 2011 to 2013. Mr. Drillick served as Chief Financial Officer for B.A.F. Management from 2010 to 2011 and Controller for Terrapin Partners from 2007 to 2010. Mr. Drillick was also a Senior Auditor of Hedge Funds at accounting firms McGladrey LLP and Deloitte LLP. Mr. Drillick earned his B.S. in accounting from Touro College where he graduated summa cum laude, and is a Certified Public Accountant. Kenneth Berkovitz, M.D., F.A.C.C., will serve as a director following the completion of this offering. Dr. Berkovitz is Senior Vice President of Ascension, a leading non-profit Catholic health system, and Ministry Market Executive of Ascension Michigan, a position he has held since February 2020. He is responsible for all aspects of the Ascension Michigan market, including its 16 hospitals and hundreds of outpatient care sites. From 2018 to 2020, Dr. Berkovitz served as president of Ascension Medical Group — Michigan, a clinically integrated multispecialty group of over 1,200 providers serving almost 600,000 patients. Additionally, Dr. Berkovitz led all state service line activity in the areas of Cardiovascular, Neuroscience, Orthopedics, Oncology and Behavioral Health while at Ascension Medical Group — Michigan. Before joining Ascension, Dr. Berkovitz held various executive leadership positions including CEO of Cardiovascular Institute at OSF Healthcare System from 2015 to 2018 and President of the Cardiovascular Institute at Summa Health System, from 2013 to 2015. He also served as Chairman of the Department of Cardiovascular Disease and System Medical Director of the Cardiovascular Service Line at Summit Health Systems from 2004 to 2015 and 2008 to 2015, respectively. Dr. Berkovitz has also been a practicing cardiologist and is a diplomate in Interventional Cardiology, Cardiovascular Disease and Internal Medicine. He earned his M.D. from Vanderbilt University School of Medicine. We believe Dr. Berkovitz is well-qualified to serve as a member of our board of directors due to his extensive experience in, and substantial understanding of, the healthcare industry and as well as his leadership positions in the sector. Christopher Kaster will serve as a director following the completion of this offering. Mr. Kaster is the founder and Chief Executive Officer of 33 BioMedical, Inc. and Alhambra Medical, Inc., two companies dedicated to developing peripheral vascular therapies, since 2019. The companies are both recent spinouts of a medical device accelerator that Mr. Kaster founded in 2019. Prior to this, Boston Scientific Corporation, a global developer, manufacturer and marketer of medical devices, hired Mr. Kaster to establish Boston Scientific Ventures (“BSC Ventures”), Boston Scientific’s venture capital arm that he managed from 2012 until his departure in 2019. Under Mr. Kaster’s leadership, BSC Ventures invested in 45 companies, deploying over $500 million in capital. Notable investments included PulmonX which went public on the Nasdaq in 2020, Cryterion, a medical device company that was acquired by Boston Scientific in 2018, and Millipede which was acquired by Boston Scientific in 2018. Mr. Kaster was an active board member or board observer on over 30 portfolio companies during his tenure at BSC Ventures. He is currently a member of the board of directors of three medical device companies, including Alleviant Medical, Inc. (since 2019), 33 Biomedical, Inc. (since 2019), and Alhambra Medical, Inc. (since 2019). Prior to joining BSC, Mr. Kaster was a General Partner at MedVenture Associates, a healthcare-focused venture capital firm, from 2003 to 2012, where he helped manage a portfolio of more than 30 investments and raise two dedicated health care funds. Mr. Kaster began his career as a Medical Technology Equity Research Analyst at investment banks WR Hambrecht + Co. in 2002 and Piper Jaffray from 2000 to 2001. Mr. Kaster earned his B.A. from St. Olaf College and his M.B.A. from the University of Minnesota, Carlson School of Business. We believe Mr. Kaster is well-qualified to serve as a member of our board of directors due to his experience managing and investing in medical technology companies, board experience, and his contacts and relationships. Ross Levine, M.D. will serve as a director following the completion of this offering. Dr. Levine is a Chief of the Molecular Cancer Medicine Service, Human Oncology and Pathogenesis Program at Memorial Sloan 123 TABLE OF CONTENTS Kettering Cancer Center, a role he has held since 2018. He is also an Attending Physician on the Leukemia Service, Department of Medicine, the Laurence Joseph Dineen Chair in Leukemia Research and a Professor of Medicine at Weill Cornell Medical College, a position he has held since 2007. Dr. Levine served as a Resident in Internal Medicine at Massachusetts General Hospital and as a Hematology-Oncology Fellow at Dana-Farber Cancer Institute. His laboratory focuses on elucidating the genetic basis of myeloid malignancies, and using this knowledge to improve outcomes for patients with these disorders. His primary research interests include the role of JAK-STAT signaling in malignant transformation and in the effects of mutations in epigenetic modifiers in clonal hematopoiesis, MPN, and AML. Moreover, as a physician scientist, his laboratory has a specific interest in translating this knowledge back to the clinic and in participating in the preclinical and clinical evaluation of targeted therapies for leukemia patients. He has been honored with the Dameshek Prize from the American Society of Hematology, a Scholar Award from the Leukemia and Lymphoma Society, the Boyer Award for Clinical Investigation from Memorial Sloan Kettering Cancer Center, and a NCI Outstanding Investigator R35 Award. In 2011, he was elected to the American Society of Clinical Investigation and in 2018 to the Association of American Physicians. Since 2016, he has served as a member of the Supervisory Board of Qiagen, and since 2019, he has served as a board member of Ajax Therapeutics, a company that he also co-founded. In addition, Dr. Levine serves on the Scientific Advisory Board of C4 Therapeutics, Isoplexis, Mana Therapeutics and was on the Scientific Advisory Board of Loxo Oncology. Dr. Levine earned his A.B. from Harvard College and a M.D. from Johns Hopkins. We believe Dr. Levine is well-qualified to serve as a member of our board of directors due to his public company board experience, and his contacts and relationships. Strategic Advisors We intend to leverage certain employees of Altium and Sio as advisors to assist us with the sourcing and evaluation of potential acquisition candidates. We believe the relationships, experience and expertise of these strategic advisors will provide us with additional access and insight into potential target companies. Our advisors do not have any written advisory agreement nor any employment or compensation arrangements with us. Joseph Gulfo, M.D., our advisor, is an Analyst at Altium, a role he has held since 2017. Dr. Gulfo has more than 25 years of experience in the biopharmaceutical and medical device industries. Dr. Gulfo served as President and Chief Executive Officer of MELA Sciences, an artificial intelligence medical diagnostics company, from 2004 to 2013 and also its chairman of the board 2011 to 2013. While at MELA Sciences, Dr. Gulfo was responsible for effecting an initial public offering and closing 11 public financings totaling approximately $160 million and obtaining FDA approval via a pre-market approval, or PMA, of MelaFind, a non-invasive instrument that aids in the detection of melanoma. As President and Chief Operating Officer of Anthra Pharmaceuticals and Chairman of its U.K. subsidiary, a role he held from 1996 to 1998, Dr. Gulfo was responsible for the FDA approval of Valstar, a chemotherapeutic drug for bladder cancer, via a new drug application, or NDA, in 1998. Dr. Gulfo was also responsible for the development of ProstaScint (Cytogen Corporation), a monoclonal antibody for prostate cancer that was approved by the FDA via a biologics license application in 1996. From 1996 to 2003, he was Chairman and Chief Executive Officer of Antigen Express, an immunotherapy and immunodiagnostics company, and led its merger. In 2012, Dr. Gulfo received the American Business Awards’ Maverick of the Year Award and was an Ernst & Young Entrepreneur of the Year Finalist. He is the author of The Care Quotient: Transforming Business Through People and Innovation Breakdown: How the FDA and Wall Street Cripple Medical Advances. He is also the author of several papers, including The Proper Role of the FDA for the 21st Century, How Can the FDA Foster Greater Resilience in the Medical Marketplace, and Product Approvability Recommendations from FDA Advisory Committees: Inconsistently Sought, Indirectly Obtained. Dr. Gulfo’s work has been published in the Wall Street Journal, Forbes, CNBC, US News & World Report, and other national publications. He teaches graduate cancer biology at Seton Hall University. Dr. Gulfo earned his B.S. in biology from Seton Hall University, his M.D. from the University of Medicine and Dentistry of New Jersey and his M.B.A. in finance from Seton Hall University. Victor Gezunterman, our advisor, is a Portfolio Manager at Altium, a role he has held since October 2020. Mr. Gezunterman has over 16 years of experience investing in, researching, and analyzing healthcare companies. Prior to joining Altium, he was responsible for medtech investing at Broadfin Capital, a healthcare-focused investment firm, as a Senior Analyst from 2017 to 2020. He started his buy-side career at 124 TABLE OF CONTENTS SAC Capital’s Sigma division in 2010, serving as a Senior Analyst until 2013. Prior to joining the buy-side, Mr. Gezunterman worked in sell-side equity research at Morgan Stanley from 2006 to 2009 and Thomas Weisel Partners (now Stifel) from 2003 to 2006, where he covered medical technology and diagnostic companies. Mr. Gezunterman started his career at Boston Biomedical Consultants, a management consulting firm, in 1997. Mr. Gezunterman earned his B.A. in Economics from Brandeis University and his M.B.A. from the University of Chicago. Eric Song, Ph.D., our advisor, is a Research Analyst at Sio since 2019. Prior to joining Sio, from 2017 to 2018, Eric worked as a sell-side equity research associate covering biotechnology at Raymond James, an investment bank. Prior to Raymond James, he was a graduate research assistant at the Miller School of Medicine at the University of Miami from 2009 to 2016. Dr. Song earned his Ph.D. in Molecular and Cellular Pharmacology from the University of Miami in 2014 and his B.S. in Clinical Pharmacy from Shenyang Pharmaceutical University. Number and Terms of Office of Officers and Directors Upon consummation of this offering, our board of directors will have five members, three of whom will be deemed “independent” under SEC and Nasdaq rules. We may not hold an annual general meeting until after we consummate our initial business combination. Prior to the completion of an initial business combination, any vacancy on the board of directors may be filled by a nominee chosen by holders of a majority of our founder shares. In addition, prior to the completion of an initial business combination, holders of a majority of our founder shares may remove a member of the board of directors for any reason. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our amended and restated memorandum and articles of association as it deems appropriate. Our amended and restated memorandum and articles of association provide that our officers may consist of one or more chairman of the board, chief executive officer, chief financial officer, chief business officer, president, vice presidents, secretary, treasurer and such other offices as may be determined by the board of directors. Director Independence Nasdaq listing standards require that a majority of our board of directors be independent. An “independent director” is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship with the company which in the opinion of the company’s board of directors, could interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director. We have “independent directors” as defined in Nasdaq’s listing standards and applicable SEC rules. Our board of directors has determined that Mr. Kaster, Dr. Levine, and Dr. Berkovitz will be “independent directors” as defined in the Nasdaq listing standards and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Any business combination must be approved by a majority of the board, including a majority of the independent directors. Executive Officer and Director Compensation Commencing on the date that our securities are first listed on Nasdaq through the earlier of consummation of our initial business combination and our liquidation, we will reimburse our sponsor for office space, secretarial and administrative services provided to us in the amount of $10,000 per month. However, we may delay payment of such monthly fee upon a determination by our audit committee that we lack sufficient funds held outside the trust to pay actual or anticipated expenses in connection with our initial business combination. Any such unpaid amount will accrue interest and be due and payable no later than the date of the consummation of our initial business combination. In addition, our sponsor, executive officers and directors or any of our or their respective affiliates will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a 125 TABLE OF CONTENTS quarterly basis all payments that were made by

Holder Stats

1 0
% of Shares Held by All Insider 0.00%
% of Shares Held by Institutions 89.18%
% of Float Held by Institutions 89.18%
Number of Institutions Holding Shares 49

Mutual Fund Holders

Holder Shares Date Reported Value % Out
Merger Fund, The 164000 2021-06-29 1582600 1.76
Saba Capital Income & Opportunities Fd 74432 2021-08-30 716035 0.8
WCM Alternatives Event Driven Fd 60000 2021-06-29 579000 0.65
RiverNorth Specialty Finance Corporation 17694 2021-06-29 170747 0.19
High Income Securities Fund 10000 2021-08-30 96200 0.11
JNL Series Trust-JNL/Multi Manager Alternative Fund 9000 2021-06-29 86850 0.1
RiverNorth Opportunities Fd 8473 2021-07-30 81426 0.09
Tidal ETF Tr-Robinson Alternative Yield Pre-Merger SPAC ETF 6412 2021-09-29 62517 0.07
Fidelity NASDAQ Composite Index Fund 6279 2021-09-29 61220 0.07
JNL Series Trust-JNL/Westchester Capital Event Driven Fund 6000 2021-06-29 57900 0.06

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2021-11-16 Schonfeld Strategic Advisors LLC 40,000 $390,000 0.0% +100.0% 0.344%
2021-11-16 CNH Partners LLC 98,630 $960,000 0.0% +78.9% 0.849%
2021-11-15 Ancora Advisors LLC 3,600 $35,000 0.0% +140.0% 0.031%
2021-11-15 Knott David M 200,000 $1,950,000 0.7% 0 1.722%
2021-11-12 Mariner Investment Group LLC 10,000 $98,000 0.3% 0 0.086%
2021-11-12 Wolverine Asset Management LLC 11,010 $110,000 0.0% +124.0% 0.095%
2021-11-09 Condor Capital Management 2,760 $27,000 0.0% +263.2% 0.024%
2021-11-09 Robinson Capital Management LLC 31,412 $310,000 0.3% 0 0.271%
2021-11-02 Wealthspring Capital LLC 141,408 $1,380,000 0.3% +20.4% 1.217%
2021-11-01 Sage Mountain Advisors LLC 179,166 $1,750,000 0.3% +4.9% 1.543%
2021-08-17 Millennium Management LLC 57,149 $550,000 0.0% 0 0.492%
2021-08-16 CNH Partners LLC 55,140 $530,000 0.0% 0 0.475%
2021-08-16 Third Point LLC 790,000 $7,620,000 0.0% 0 6.802%
2021-08-16 Fir Tree Capital Management LP 46,000 $440,000 0.0% 0 0.396%
2021-08-16 Rivernorth Capital Management LLC 50,000 $480,000 0.0% 0 0.430%
2021-08-16 Schonfeld Strategic Advisors LLC 20,000 $190,000 0.0% 0 0.172%
2021-08-16 Kingdon Capital Management L.L.C. 300,000 $2,900,000 0.3% 0 2.583%
2021-08-16 Radcliffe Capital Management L.P. 11,883 $120,000 0.0% 0 0.102%
2021-08-16 Goldman Sachs Group Inc. 16,918 $160,000 0.0% 0 0.146%
2021-08-16 Periscope Capital Inc. 100,000 $970,000 0.0% 0 0.861%
2021-08-13 RTW Investments LP 300,000 $2,900,000 0.0% 0 2.583%
2021-08-13 Alpine Global Management LLC 43,067 $420,000 0.1% 0 0.371%
2021-08-13 GABELLI & Co INVESTMENT ADVISERS INC. 15,400 $150,000 0.0% 0 0.133%
2021-08-13 Gabelli Funds LLC 14,600 $140,000 0.0% 0 0.126%
2021-08-13 Affinity Asset Advisors LLC 300,000 $2,900,000 1.0% 0 2.583%
2021-08-13 Glazer Capital LLC 454,077 $4,380,000 0.1% 0 3.909%
2021-08-13 OLD Mission Capital LLC 14,362 $140,000 0.0% 0 0.124%
2021-08-13 Westchester Capital Management LLC 239,000 $2,310,000 0.1% 0 2.058%
2021-08-12 Kepos Capital LP 525,000 $5,070,000 0.4% 0 4.520%
2021-08-12 Littlejohn & Co. LLC 20,000 $190,000 0.1% 0 0.172%
2021-08-11 Cowen Investment Management LLC 75,000 $720,000 0.2% 0 0.646%
2021-08-06 JW Asset Management LLC 100,000 $970,000 0.2% 0 0.861%
2021-08-06 HighTower Advisors LLC 40,560 $390,000 0.0% 0 0.349%
2021-08-02 Wealthspring Capital LLC 300,824 $2,900,000 0.4% 0 2.590%
2021-07-31 Sage Mountain Advisors LLC 170,836 $1,650,000 0.3% 0 1.471%

SEC Filings

Form Type Form Description Filing Date Document Link
10-Q FORM 10-Q 2021-11-04 https://www.sec.gov/Archives/edgar/data/1836517/000110465921134479/msacu-20210930x10q.htm
10-Q FORM 10-Q 2021-08-05 https://www.sec.gov/Archives/edgar/data/1836517/000110465921100795/msacu-20210630x10q.htm
SC 13G FORM SC 13G 2021-08-05 https://www.sec.gov/Archives/edgar/data/1836517/000106299321007086/formsc13g.htm
10-Q FORM 10-Q 2021-05-24 https://www.sec.gov/Archives/edgar/data/1836517/000110465921070794/msacu-20210331x10q.htm
NT 10-Q NT 10-Q 2021-05-17 https://www.sec.gov/Archives/edgar/data/1836517/000110465921068008/a21-13291_2nt10q.htm
25-NSE 2021-04-07 https://www.sec.gov/Archives/edgar/data/1836517/000135445721000451/xslF25X02/primary_doc.xml
8-K FORM 8-K 2021-04-01 https://www.sec.gov/Archives/edgar/data/1836517/000110465921045600/tm2111538d1_8k.htm
10-K FORM 10-K 2021-03-31 https://www.sec.gov/Archives/edgar/data/1836517/000110465921044651/tm2110511d1_10k.htm
SC 13G MEDICUS SCIENCES ACQUISITION CORP. 2021-03-01 https://www.sec.gov/Archives/edgar/data/1836517/000090266421001666/p21-0852sc13g.htm
SC 13G SC 13G 2021-02-26 https://www.sec.gov/Archives/edgar/data/1836517/000110465921029151/tm218097d1_sc13g.htm
8-K FORM 8-K 2021-02-24 https://www.sec.gov/Archives/edgar/data/1836517/000110465921027485/tm2038331d15_8k.htm
8-K FORM 8-K 2021-02-19 https://www.sec.gov/Archives/edgar/data/1836517/000110465921025832/tm2038331d14_8k.htm
424B4 424B4 2021-02-17 https://www.sec.gov/Archives/edgar/data/1836517/000110465921024703/tm2038331-13_424b4.htm
CERT 2021-02-16 https://www.sec.gov/Archives/edgar/data/1836517/000135445721000223/8A_Cert_MSAC.pdf
EFFECT 2021-02-12 https://www.sec.gov/Archives/edgar/data/1836517/999999999521000637/xslEFFECTX01/primary_doc.xml
3 3 2021-02-12 https://www.sec.gov/Archives/edgar/data/1836517/000110465921022321/xslF345X02/a3.xml
3 3 2021-02-12 https://www.sec.gov/Archives/edgar/data/1836517/000110465921022319/xslF345X02/a3.xml
3 3 2021-02-12 https://www.sec.gov/Archives/edgar/data/1836517/000110465921022318/xslF345X02/a3.xml
3 3 2021-02-12 https://www.sec.gov/Archives/edgar/data/1836517/000110465921022317/xslF345X02/a3.xml
3 3 2021-02-12 https://www.sec.gov/Archives/edgar/data/1836517/000110465921022313/xslF345X02/a3.xml
3 3 2021-02-12 https://www.sec.gov/Archives/edgar/data/1836517/000110465921022311/xslF345X02/a3.xml
3 3 2021-02-12 https://www.sec.gov/Archives/edgar/data/1836517/000110465921022310/xslF345X02/a3.xml
3 3 2021-02-12 https://www.sec.gov/Archives/edgar/data/1836517/000110465921022309/xslF345X02/a3.xml
8-A12B 8-A12B 2021-02-12 https://www.sec.gov/Archives/edgar/data/1836517/000110465921021886/a20-38331_128a12b.htm
CORRESP 2021-02-10 https://www.sec.gov/Archives/edgar/data/1836517/000110465921019954/filename1.htm
CORRESP 2021-02-10 https://www.sec.gov/Archives/edgar/data/1836517/000110465921019953/filename1.htm
S-1/A FORM S-1/A 2021-02-03 https://www.sec.gov/Archives/edgar/data/1836517/000110465921011139/tm2038331d9_s1a.htm
CORRESP 2021-01-28 https://www.sec.gov/Archives/edgar/data/1836517/000110465921008714/filename1.htm
S-1/A S-1/A 2021-01-28 https://www.sec.gov/Archives/edgar/data/1836517/000110465921008710/tm2038331-3_s1a.htm
UPLOAD 2021-01-21 https://www.sec.gov/Archives/edgar/data/1836517/000000000021000758/filename1.pdf
S-1 S-1 2020-12-23 https://www.sec.gov/Archives/edgar/data/1836517/000110465920139241/tm2038331-1_s1.htm